Cost-Effectiveness of Balloon Kyphoplasty : A Swedish Multicenter Randomized Controlled Trial With 2-Year Follow-upVersus: A Swedish Multicenter Randomized Controlled Trial With 2-Year Follow-up Standard Medical Treatment in Patients With Osteoporotic Vertebral Compression Fracture: A Swedish Multicenter Randomized Controlled Trial With 2-Year Follow-up

    loading  Checking for direct PDF access through Ovid

Abstract

Study Design.

A multicenter, randomized, controlled, cost-effectiveness analysis.

Objective.

To assess the cost-effectiveness of balloon kyphoplasty (BKP) compared with standard medical treatment (control) in patients with acute/subacute (<3 months) vertebral compression fracture (VCF) due to osteoporosis.

Summary of Background Data.

Patients with a VCF due to osteoporosis are common and will increase in number in an aging population, putting a substantial strain on health care. Selected patients may benefit from stabilizing the fracture with cement through BKP, a minimally invasive procedure. BKP has been reported to give good short-time clinical results, and economic modeling has suggested that the procedure could be cost-effective after 2 years compared with standard treatment.

Methods.

Hospitalized patients with back pain due to VCF were randomized to BKP or to control using a computer-generated random list. All costs associated with VCF and cost-effectiveness were reported primarily from the perspective of society. We used EQ-5D to assess quality of life (QoL). The accumulated quality-adjusted life years (QALYs) gained and costs/QALY gained were assessed using intention to treat.

Results.

Between February 2003 and December 2005, a total of 63 out of 67 Swedish patients were analyzed: BKP (n = 32) and control (n = 31). Societal cost per patient for BKP was SEK 160,017 (SD = 151,083) = €16,668 (SD = 15,735), and for control SEK 84,816 (SD = 40,954) = €8835 (SD = 4266), a significant difference of 75,198 (95% confidence intervals [CI] = 16,037–120,104) = €7833 (95% CI = 1671–12,511). The accumulated difference in QALYs was 0.085 (95% CI = −0.132 to 0.306) in favor of BKP. Cost/QALY gained using BKP was SEK 884,682 = €92,154 and US $134,043.

Conclusion.

In this randomized controlled trial, it was not possible to demonstrate that BKP was cost-effective compared with standard medical treatment in patients treated for an acute/subacute vertebral fracture due to osteoporosis. However, sensitivity analysis indicated a certain degree of uncertainty, which needs to be considered.

Related Topics

    loading  Loading Related Articles